In win for compounders, FDA will review its decision to put Eli Lilly's tirzepatide on shortage list
In accepting the FDA’s motion, U.S. District Judge Mark Pittman put on hold a lawsuit filed by the Outsourcing Facilities Association (OFA), which called the FDA’s decision to remove tirzepatide from the shortage list a “reckless and arbitrary decision—lacking any semblance of lawful process.”
Lilly, weight loss
The case for Novo Nordisk. Right now Novo Nordisk has a considerable lead on Lilly in GLP-1 market share, and a couple of ...
The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...
Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...
DBS analyst Nico Chen has maintained their bullish stance on LLY stock, giving a Buy rating yesterday. Nico Chen has given his Buy rating due ...
Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.
Eli Lilly is expanding its innovation digs to Beijing, opening two research centers called the Eli Lilly China Medical ...
Eli Lilly and Co. (LLY) is planning to invest $364 million or 279 million pounds in the biotechnology segment in the U.K., to ...
Eli Lilly’s senior VP of information and R&D IT, Ramesh Durvasula, said Lilly will use AI and tech to transform the company.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback